Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06656598 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Study acronym: SPORADIC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 24 words Secondary endpoints: 12 to 13v4 Show 1 more changeShow less
    • Secondary endpoints: 12 to 13

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2025 to Nov 7, 2025 · Study sites: 26 to 25v3 Show 2 more changesShow less
    • Start date changed from estimate of Apr 2025 to Nov 7, 2025
    • Study sites: 26 to 25
  3. Start date: Jan 2025 to Apr 2025 Site contacts updated at 26 of 26 sites · Study title shortened, about 5 wordsv2 Show 2 more changesShow less
    • Site contacts updated at 26 of 26 sites
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
Trial Details
NCT Number NCT06656598
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Stage III NSCLC
Enrollment 152 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov